The contribution of real-world evidence to cost-effectiveness analysis: case study of Dabigatran etexilate in France

ConclusionThe reassessment of outcomes and cost data had an impact on results, improving the efficiency of Dabigatran. We identify methodological issues which should be discussed if post-launch RWE based cost-effectiveness data become a standard in HTA decision making.
Source: The European Journal of Health Economics - Category: Health Management Source Type: research